Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

A Randomized, Active-Controlled, Double-Blind, Parallel Design, Multi-Center, Phase III Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Patients With Benign Prostatic Hyperplasia (BPH)

The current study is being conducted by the Sponsor to evaluate the efficacy and safety of GV1001 (0.56 mg and 1.12 mg) administered as a treatment for Benign prostate hyperplasia(BPH). The investigational drug, GV1001, was first developed as a cancer vaccine for use as active immunotherapy of cancer forms expressing telomerase (eg, pancreatic cancer, prostate cancer, etc.). Subsequently, it was found that GV1001 showed efficacy in alleviating BPH symptoms during in vivo studies by reducing the size of the prostate gland. Based on the result, the effectiveness of GV1001 as a treatment for BPH has been assessed in experimental animals that are designed to develop BPH.

It is considered that GV1001 acts to alleviate BPH and the results obtained from previous phase II study indicate that GV1001 may provide potential beneficial effects in BPH patients.

So this study is to verify the efficacy and safety of GV1001 on BPH population, large-scale clinical study than phase II.

Study Overview

• Status: Completed
• Conditions: Benign Prostatic Hyperplasia (BPH)
• Intervention / Treatment: Drug: GV1001 placebo; Drug: Proscar placebo

Detailed Description

This was a multi-center, randomized, Double-blind, Active-controlled, parallel design, Phase 3 study in patients with BPH. The study consisted of a Screening period, a 4-weeks Run-in/Washout period, a 24-week Treatment period, an Evaluation and Close-out Visit at Week 24.

There are a total of 3 groups in this study, which contained 2 study groups (GV1001) and 1 placebo group (0.9% normal saline). Approximately 417 patients are planned to be randomly assigned into the study in a 1:1:1 ratio. All patients are randomized into 1 of 3 treatment groups to ensure completion of patients.

The Screening period have a time period of 4 weeks before the beginning of Run-in/Washout period. Eligible patients entered into a 4-week Run-in/Washout period and receive placebo treatment, which will be completed before randomization on Week 0. All randomized patients will receive the investigational drug or a placebo via intradermal injection 12 times with a 2-week interval at Weeks 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. Efficacy evaluation will be conducted at Weeks 4, 8, 12, 16, 20 and 24, and safety evaluation will be conducted throughout the 24-weeks period.

• Study Type: Interventional
• Enrollment (Actual): 423
• Phase: Phase 3

Contacts and Locations

Study Locations

• Korea, Republic of
  • Anyang, Korea, Republic of
    • Hallym University Medical Center
  • Busan, Korea, Republic of
    • Inje University Busan Paik Hospital
  • Changwon, Korea, Republic of
    • Samsung Changwon Medical Center
  • Cheonan, Korea, Republic of
    • Soonchunhyang University Hospital
  • Chungbuk, Korea, Republic of
    • Chungbuk National University Hospital
  • Chungnam, Korea, Republic of
    • Chonnam National University Hospital
  • Daegu, Korea, Republic of
    • Daegu Catholic University Medical Center
  • Daegu, Korea, Republic of
    • Keimyung University Dongsan Medical Center
  • Daegu, Korea, Republic of
    • Kyungpook National University Chilgok Hospital
  • Daegu, Korea, Republic of
    • Yeungnam University Medical Center
  • Ilsan, Korea, Republic of
    • Dongguk University Ilsan Hospital
  • Jeonju, Korea, Republic of
    • Jeonbuk National University Hospital
  • Seoul, Korea, Republic of
    • Asan Medical Center
  • Seoul, Korea, Republic of
    • Samsung Medical Center
  • Seoul, Korea, Republic of
    • Eulji General Hospital
  • Seoul, Korea, Republic of
    • Chung-Ang University Hospital
  • Seoul, Korea, Republic of
    • Korea University Guro Hospital
  • Seoul, Korea, Republic of
    • Severance Hospital
  • Seoul, Korea, Republic of
    • The Catholic University of Korea, Seoul St. Mary's Hospital
  • Yangsan, Korea, Republic of
    • Pusan National University Yangsan Hospital
  • Gyeonggi-do
    • Guri-si, Gyeonggi-do, Korea, Republic of
      • Hanyang University Guri Hospital
    • Seongnam-si, Gyeonggi-do, Korea, Republic of
      • Seoul National University Bundang Hospital
  • Gyeongsangbuk-do
    • Gyeongju, Gyeongsangbuk-do, Korea, Republic of
      • Dongguk university gyeongju hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 48 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

1. A male at 50 years of age and older

2. Clinical signs and symptoms of benign prostatic hyperplasia

   1. A volume of prostate gland (TRUS) > 30 cc
   2. Moderate to severe lower urinary tract symptoms with IPSS ≥ 13
   3. 5-15 mL/sec of maximum flow rate (Qmax) measured when urine volume was at least 125 mL
3. PSA level < 10 ng/mL (however, if 4 ng/mL < PSA < 10 ng/mL, a person with a biopsy result, confirming that he does not have prostate cancer)
4. Residual urine volume ≤ 200 Ml
5. Consent not to participate in other clinical trials as a subject during this clinical trial period.

6. Consent of patient and patient's partner a. Patient

   • Consent to avoid pregnancy by using condoms for 90 days after the end of study participation period and treatment. (Not applied if the patient had vasectomy.) b. Patient's partner (Consent should be obtained before visit 4, when necessary.)
   • Consent to avoid pregnancy by using contraceptive devices or oral contraceptives during the patient's participation in clinical trial and for 90 days after the end of treatment, except if the partner reaches menopause or is surgically sterilized.

Exclusion Criteria:

1. Hypersensitivity reactions to ingredients of this drug.
2. Taking drugs that affect the results of clinical trials. ex) 5-alpha reductase inhibitors, drugs similar to LHRH, alpha blockers, alpha-beta blockers, anticholinergics, antidiuretic hormones, diuretics, PDE-5 inhibitors, beta-3 adrenoceptor antagonists, steroids, immune suppressants, saw palmetto, etc.
3. Taking drugs of an unapproved study drug in the past or the study drug for this clinical trial
4. Diagnosis with prostate cancer in the past or at present
5. Diagnosis by an investigator to have an influence to an evaluation on urine flow symptoms due to other previous or current diseases besides benign prostatic hyperplasia
6. Surgeries or radiation therapies for prostate gland, bladder or pelvis, or who had invasive treatments for benign prostatic hyperplasia
7. Severe medical condition which may be cause problem to conduct the clinical trial (e.g., chronic heart failure (CHF), difficult-to-control diabetes (HbA1c > 7%), mental disorder, drug, or alcohol abuse, etc.)
8. Moderate to severe liver hypofunction and severe kidney hypofunction (less than 30 mL/min of creatinine clearance)
9. Any other subjects who are considered to be ineligible for this study by an investigator

[Inclusion Criteria for Randomization]

1. Clinical signs and symptoms of benign prostatic hyperplasia

   1. Volume of prostate gland (TRUS) > 30 cc *
   2. moderate to severe lower urinary tract symptoms with IPSS ≥ 13
   3. 5-15 mL/sec of maximum flow rate (Qmax) measured when urine volume was at least 125 mL
2. Residual urine volume ≤ 200 mL
3. Patient's partner (Consent should be obtained before visit 4, when necessary.) - Consent to avoid pregnancy by using contraceptive devices or oral contraceptives during the patient's participation in clinical trial and for 90 days after the end of treatment, except if the partner reaches menopause or is surgically sterilized.

(* In case that additional TRUS examination has been performed after screening, a decision should be made based on the latest result.)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Control Group; GV1001-Placebo ID injection administered every 2 weeks through Week 24 + Proscar PO administered once a day through Week 24	Drug: GV1001 placebo; 0.9 % Normal Saline; Other Names: Normal Saline
Experimental: Study Group 1; GV1001 0.56 mg ID injection administered every 2 weeks through Week 24 + Proscar-placebo PO administered once a day through Week 24	Drug: Proscar placebo; PO; Other Names: Finasteride
Experimental: Study Group 2; GV1001 1.12 mg ID injection administered every 2 weeks through Week 24 + Proscar-placebo PO administered once a day through Week 24	Drug: Proscar placebo; PO; Other Names: Finasteride

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in International Prostate Symptom Score(IPSS)	The amount of change from International Prostate Symptom Score(IPSS )compared to the baseline. The measures of the 7 items evaluating symptoms is evaluated from 0 to 5 for each item, the total coverage range is from 0 (no symptoms) to 35 (most severe symptoms). And the quality of life assessment is assessed from 0 (very satisfactory) to 6 (very unsatisfactory).	Week 24

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in International Prostate Symptom Score(IPSS)	The amount of change from International Prostate Symptom Score(IPSS )compared to the baseline. The measures of the 7 items evaluating symptoms is evaluated from 0 to 5 for each item, the total coverage range is from 0 (no symptoms) to 35 (most severe symptoms). And the quality of life assessment is assessed from 0 (very satisfactory) to 6 (very unsatisfactory).	Weeks 4, 8, 12, 16 and 20
Change in voiding score of International Prostate Symptom Score(IPSS)	The amount of change from voiding score of IPSS compared to the baseline. The voiding score is measured as the sum of the evaluation scores of items 1, 3, 5 and 6 of the seven symptom scores of the IPSS.	Weeks 4, 8, 12, 16, 20 and 24
Change in Prostatic Volume(PV)	The amount of change from Prostatic Volume(PV) compared to the baseline.	Weeks 12 and 24
Change in Maximum(peak) Urinary Flow Rate	The amount of change from Maximum(peak) Urinary Flow Rate compared to the baseline	Weeks 12 and 24
Change in Prostate-specific Antigen (PSA)	The amount of change from Prostate-specific Antigen (PSA) compared to the baseline	Weeks 12 and 24
Change in Residual Urine Volume	The amount of change from Residual Urine Volume compared to the baseline	Weeks 12 and 24
Change in Hormones (Testosterone, DHT)	The amount of change from Hormones (Testosterone, DHT) compared to the baseline	Weeks 4, 8, 12, 16, 20 and 24
Change in International Index of Erectile Function (IIEF)	The amount of change from International Index of Erectile Function (IIEF) compared to the baseline	Weeks 4, 8, 12, 16, 20 and 24
rate of incidence of Acute urinary tract(AUR)	The rate of incidence of Acute urinary tract(AUR), meaning clinical progression of prostate hypertrophy	Every 2 weeks After screening visit up to 24 week
Ratio of prostate surgery and minimally invasive (non-surgical) procedure	The ratio of prostate surgery and minimally invasive (non-surgical) procedure, meaning clinical progression of prostate hypertrophy	Every 2 weeks After screening visit up to 24 week

Collaborators and Investigators

• Sponsor: GemVax & Kael

Study record dates

Study Major Dates

• Study Start (Actual): October 30, 2019
• Primary Completion (Actual): March 17, 2022
• Study Completion (Actual): March 17, 2022

Study Registration Dates

• First Submitted: July 19, 2019
• First Submitted That Met QC Criteria: July 23, 2019
• First Posted (Actual): July 25, 2019

Study Record Updates

• Last Update Posted (Actual): August 25, 2022
• Last Update Submitted That Met QC Criteria: August 24, 2022
• Last Verified: February 1, 2022

More Information

Terms related to this study

• Keywords: Benign Prostatic Hyperplasia; GV1001
• Additional Relevant MeSH Terms: Pathologic Processes; Prostatic Diseases; Prostatic Hyperplasia; Hyperplasia; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Urological Agents; Enzyme Inhibitors; Hormones, Hormone Substitutes, and Hormone Antagonists; Hormone Antagonists; Steroid Synthesis Inhibitors; 5-alpha Reductase Inhibitors; Finasteride
• Other Study ID Numbers: KG8/2019

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No